Surgical Science Sweden (SUSR.F) Stock Overview
Develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SUSR.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Surgical Science Sweden AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 4.00 |
| 52 Week High | SEK 15.47 |
| 52 Week Low | SEK 2.84 |
| Beta | 0.60 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -71.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| SUSR.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | -1.4% |
| 1Y | n/a | -21.8% | 16.4% |
Return vs Industry: Insufficient data to determine how SUSR.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how SUSR.F performed against the US Market.
Price Volatility
| SUSR.F volatility | |
|---|---|
| SUSR.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SUSR.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SUSR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 317 | Tom Englund | www.surgicalscience.com |
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnostic and therapeutic hysteroscopy training; URO Mentor, a virtual reality simulator for endourology training; EndoSim, a realistic scope simulator; FlexVR, a flexible and portable training platform which is designed to teach basic and advanced skills for robotic surgery; and LAP Mentor provides a wide array of laparoscopic training cases. It also provides LapSim training system comprising LapSim Haptic simulator that provides laparoscopic training; LapSim essence, a portable and ready-to-use VR simulator; and LapSim 360, which provides a high-immersion virtual reality training experience; MentorLearn, an end-to-end educational platform that makes simulation course management; and LapSim ST, a training system that prepares students for the operating room.
Surgical Science Sweden AB (publ) Fundamentals Summary
| SUSR.F fundamental statistics | |
|---|---|
| Market cap | US$159.73m |
| Earnings (TTM) | US$5.38m |
| Revenue (TTM) | US$100.75m |
Is SUSR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUSR.F income statement (TTM) | |
|---|---|
| Revenue | SEK 977.14m |
| Cost of Revenue | SEK 337.09m |
| Gross Profit | SEK 640.05m |
| Other Expenses | SEK 587.84m |
| Earnings | SEK 52.21m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 19, 2026
| Earnings per share (EPS) | 1.02 |
| Gross Margin | 65.50% |
| Net Profit Margin | 5.34% |
| Debt/Equity Ratio | 0.05% |
How did SUSR.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/23 11:53 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Surgical Science Sweden AB (publ) is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Simon Jonsson | Berenberg |
| Simon Larsson | Danske Bank |
| Kristofer Liljeberg-Svensson | DNB Carnegie |